Press releases

Guard Therapeutics announced today that, through the European application procedure, the company has received authorization from regulatory authorities and ethics committees in Spain, Germany, and the Czech Republic to include patients in the clinical Phase 2b study POINTER with the drug candidate RMC-035 as a kidney-protective treatment in...

Guard Therapeutics today announced that the scientific journal American Journal of Physiology – Renal Physiology has published an article summarizing important preclinical results of the company's clinical drug candidate RMC-035. The results consistently demonstrate positive effects of RMC-035 in a large number of models for kidney injury...

Guard Therapeutics [GUARD], a biotechnology company specializing in kidney diseases, announced today that the company conducted a digital R&D Update on January 30, 2024. The presentation included an update on next development steps for the drug candidate RMC-035 and progress within the preclinical development platform of new peptides intended...

Guard Therapeutics [GUARD], a biotechnology company specialized in kidney diseases, announced today that the company is organizing a digital R&D Update on January 30, 2024, from 14:00 to 15:30. The company will discuss the results of the completed Phase 2 AKITA study and the continued development plan for the company’s lead candidate RMC-035...

Guard Therapeutics International AB (publ) today announces that a Nomination Committee has been appointed in accordance with previous AGM resolutions.